HDAC8-IN-12
HDAC8-IN-12 (compound 5k) is a non-hydroxamic acid, selective inhibitor of HDAC8 (IC50: 0.12 nM) and a potent inhibitor of breast cancer. HDAC8-IN-12 triggers anti-tumor immunity by activating T cells, increasing the proportion of M1 macrophages and decreasing the proportion of M2 macrophages. HDAC8-IN-12 (50 mg/kg) exerts tumor suppressive effects in an orthotopic mouse model of breast cancer[1].
Product Specifications
CAS Number
3028095-13-5
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac8-in-12.html
Smiles
CN(/C1=C\C2=CC=C(C(OC)=C2)/C=C/C(NO)=O)C(CNC1=O)=O
Molecular Formula
C16H17N3O5
Molecular Weight
331.32
References & Citations
[1]Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (156-3C11), CF594 conjugate, 0.1mg/mL
Human IgG Immunoglobulin (IG266), CF568 conjugate, 0.1mg/mL
MART-1 / Melan-A (M2-7C10), CF640R conjugate, 0.1mg/mL
Cytokeratin 8/18 (C-51), CF740 conjugate, 0.1mg/mL
